Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.
Eric F MorandJosef S SmolenMichelle PetriYoshiya TanakaMaria SilkChristina DicksonGabriella MeszarosInmaculada de la TorreMaher IssaHong ZhangThomas DörnerPublished in: RMD open (2023)
The results of this integrated safety analysis in patients with SLE are not substantially different to the established safety profile of baricitinib. No increased venous thromboembolism was found.